Top Companies in the Exosome Diagnostic and Therapeutic Market
The global exosome diagnostic and therapeutic market size was predicted at US$ 33.04 million in 2023 and is projected to grow to US$ 22,609.77 million by 2034, rising at a compound annual growth rate (CAGR) of 81.03% from 2024 to 2034.
Exosome Diagnostic and Therapeutic Key Players:
- Thermo Fisher Scientific Inc.
- Exosome Diagnostics
- QIAGEN
- System Biosciences LLC
- ReNeuron
- Hitachi Chemical Diagnostics Inc.
- Capricor Therapeutics Inc.
- Evox Therapeutics
- Bio-Techne
- Capital Biosciences Inc.
- Exogenus Therapeutics
- Exo Biologics
Latest Announcements by Industry Leaders
- In November 2024, Nitin Sood, Vice President and Head of the Life Sciences Business Area at QIAGEN, reported that the QIAGEN collaboration with McGill University to advance microbiome research will help QIAGEN develop new microbiome solutions.
- In February 2024, Kim Kelderman, president and chief executive officer of Bio-Techne, said that the unique life science tools and diagnostics portfolio, experienced team, financial strength, and deep scientific capabilities of Bio-Techne are positioning the company to establish value for all of its stakeholders going forward.
- In September 2024, Leon Wyszkowski, president of analytical services and clinical research at Thermo Fisher Scientific, announced the expansion of the company’s bioanalytical footprint in Europe in the innovative and collaborative environment of GoCo Health Innovation City through the deployment of technologically advanced systems and for developing assays.
Recent Development in the Exosome Diagnostic and Therapeutic Market
- In May 2024, Capricor Therapeutics Inc. introduced the potential of an exosome-based approach for the treatment of arginase-1 deficiency (ARG1-D), which is a rare genetic metabolic disease characterized by a complete or a partial lack of arginase enzyme in the liver and red blood cells.
- In April 2024, Exo Biologics announced the securing of up to EUR 16 million in series A funding for developments in exosome therapeutic and clinical supply. These funds will support the ongoing and future clinical trials.
If you have any questions, please feel free to contact us at
